Tango Therapeutics, Inc.
TNGX · XNASCIK 1819133fmd_0Q1P3J0WFT5VGFHV3V7XP5NTSDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 8 | 37 | 25 | 37 | 42 | 62 |
| Net interest income | 0 | 0 | 1 | 7 | 8 | 6 |
| Research and development | 50 | 78 | 106 | 115 | 144 | 132 |
| Total operating expenses | 60 | 95 | 136 | 151 | 188 | 174 |
| Operating income | (52) | (58) | (111) | (114) | (146) | (111) |
| Other non-operating income (expense) | 0 | 0 | 3 | 13 | 16 | 10 |
| Income before taxes | (52) | (58) | (108) | (102) | (130) | (102) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (52) | (58) | (108) | (102) | (130) | (102) |
| Net income | (52) | (58) | (108) | (102) | (130) | (102) |